Literature DB >> 28198005

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update.

J A Johnson1, K E Caudle2, L Gong3, M Whirl-Carrillo3, C M Stein4, S A Scott5, M T Lee6, B F Gage7, S E Kimmel8,9, M A Perera10, J L Anderson11, M Pirmohamed12, T E Klein3, N A Limdi13, L H Cavallari1, M Wadelius14.   

Abstract

This document is an update to the 2011 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing. Evidence from the published literature is presented for CYP2C9, VKORC1, CYP4F2, and rs12777823 genotype-guided warfarin dosing to achieve a target international normalized ratio of 2-3 when clinical genotype results are available. In addition, this updated guideline incorporates recommendations for adult and pediatric patients that are specific to continental ancestry.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28198005      PMCID： PMC5546947          DOI： 10.1002/cpt.668

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  43 in total

1.  Oral anticoagulation and risk of death: a medical record linkage study.

Authors:  Anders Odén; Martin Fahlén
Journal:  BMJ       Date:  2002-11-09

2.  Genetic warfarin dosing: tables versus algorithms.

Authors:  Brian S Finkelman; Brian F Gage; Julie A Johnson; Colleen M Brensinger; Stephen E Kimmel
Journal:  J Am Coll Cardiol       Date:  2011-02-01       Impact factor: 24.094

3.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network.

Authors:  M V Relling; T E Klein
Journal:  Clin Pharmacol Ther       Date:  2011-01-26       Impact factor: 6.875

4.  Integration of genetic, clinical, and INR data to refine warfarin dosing.

Authors:  P Lenzini; M Wadelius; S Kimmel; J L Anderson; A L Jorgensen; M Pirmohamed; M D Caldwell; N Limdi; J K Burmester; M B Dowd; P Angchaisuksiri; A R Bass; J Chen; N Eriksson; A Rane; J D Lindh; J F Carlquist; B D Horne; G Grice; P E Milligan; C Eby; J Shin; H Kim; D Kurnik; C M Stein; G McMillin; R C Pendleton; R L Berg; P Deloukas; B F Gage
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

5.  Increased production of functional recombinant human clotting factor IX by baby hamster kidney cells engineered to overexpress VKORC1, the vitamin K 2,3-epoxide-reducing enzyme of the vitamin K cycle.

Authors:  Nadeem Wajih; Susan M Hutson; John Owen; Reidar Wallin
Journal:  J Biol Chem       Date:  2005-07-19       Impact factor: 5.157

6.  A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.

Authors:  P J Avery; A Jorgensen; A K Hamberg; M Wadelius; M Pirmohamed; F Kamali
Journal:  Clin Pharmacol Ther       Date:  2011-09-28       Impact factor: 6.875

7.  Congenital deficiency of vitamin K dependent coagulation factors in two families presents as a genetic defect of the vitamin K-epoxide-reductase-complex.

Authors:  J Oldenburg; B von Brederlow; A Fregin; S Rost; W Wolz; W Eberl; S Eber; E Lenz; R Schwaab; H H Brackmann; W Effenberger; U Harbrecht; L J Schurgers; C Vermeer; C R Müller
Journal:  Thromb Haemost       Date:  2000-12       Impact factor: 5.249

8.  A pharmacogenetic versus a clinical algorithm for warfarin dosing.

Authors:  Stephen E Kimmel; Benjamin French; Scott E Kasner; Julie A Johnson; Jeffrey L Anderson; Brian F Gage; Yves D Rosenberg; Charles S Eby; Rosemary A Madigan; Robert B McBane; Sherif Z Abdel-Rahman; Scott M Stevens; Steven Yale; Emile R Mohler; Margaret C Fang; Vinay Shah; Richard B Horenstein; Nita A Limdi; James A S Muldowney; Jaspal Gujral; Patrice Delafontaine; Robert J Desnick; Thomas L Ortel; Henny H Billett; Robert C Pendleton; Nancy L Geller; Jonathan L Halperin; Samuel Z Goldhaber; Michael D Caldwell; Robert M Califf; Jonas H Ellenberg
Journal:  N Engl J Med       Date:  2013-11-19       Impact factor: 91.245

9.  Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis.

Authors:  Ruijuan Liang; Chunling Wang; Hong Zhao; Jie Huang; Dayi Hu; Yihong Sun
Journal:  Thromb Res       Date:  2011-12-20       Impact factor: 3.944

10.  The largest prospective warfarin-treated cohort supports genetic forecasting.

Authors:  Mia Wadelius; Leslie Y Chen; Jonatan D Lindh; Niclas Eriksson; Mohammed J R Ghori; Suzannah Bumpstead; Lennart Holm; Ralph McGinnis; Anders Rane; Panos Deloukas
Journal:  Blood       Date:  2008-06-23       Impact factor: 22.113
View more
  149 in total

1.  Standardized Biogeographic Grouping System for Annotating Populations in Pharmacogenetic Research.

Authors:  Rachel Huddart; Alison E Fohner; Michelle Whirl-Carrillo; Genevieve L Wojcik; Christopher R Gignoux; Alice B Popejoy; Carlos D Bustamante; Russ B Altman; Teri E Klein
Journal:  Clin Pharmacol Ther       Date:  2019-01-21       Impact factor: 6.875

2.  Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.

Authors:  Elisa Danese; Sara Raimondi; Martina Montagnana; Angela Tagetti; Taimour Langaee; Paola Borgiani; Cinzia Ciccacci; Antonio J Carcas; Alberto M Borobia; Hoi Y Tong; Cristina Dávila-Fajardo; Mariana Rodrigues Botton; Stephane Bourgeois; Panos Deloukas; Michael D Caldwell; Jim K Burmester; Richard L Berg; Larisa H Cavallari; Katarzyna Drozda; Min Huang; Li-Zi Zhao; Han-Jing Cen; Rocio Gonzalez-Conejero; Vanessa Roldan; Yusuke Nakamura; Taisei Mushiroda; Inna Y Gong; Richard B Kim; Keita Hirai; Kunihiko Itoh; Carlos Isaza; Leonardo Beltrán; Enrique Jiménez-Varo; Marisa Cañadas-Garre; Alice Giontella; Marianne K Kringen; Kari Bente Foss Haug; Hye Sun Gwak; Kyung Eun Lee; Pietro Minuz; Ming Ta Michael Lee; Steven A Lubitz; Stuart Scott; Cristina Mazzaccara; Lucia Sacchetti; Ece Genç; Mahmut Özer; Anil Pathare; Rajagopal Krishnamoorthy; Andras Paldi; Virginie Siguret; Marie-Anne Loriot; Vijay Kumar Kutala; Guilherme Suarez-Kurtz; Jamila Perini; Josh C Denny; Andrea H Ramirez; Balraj Mittal; Saurabh Singh Rathore; Hersh Sagreiya; Russ Altman; Mohamed Hossam A Shahin; Sherief I Khalifa; Nita A Limdi; Charles Rivers; Aditi Shendre; Chrisly Dillon; Ivet M Suriapranata; Hong-Hao Zhou; Sheng-Lan Tan; Vacis Tatarunas; Vaiva Lesauskaite; Yumao Zhang; Anke H Maitland-van der Zee; Talitha I Verhoef; Anthonius de Boer; Monica Taljaard; Carlo Federico Zambon; Vittorio Pengo; Jieying Eunice Zhang; Munir Pirmohamed; Julie A Johnson; Cristiano Fava
Journal:  Clin Pharmacol Ther       Date:  2019-02-17       Impact factor: 6.875

3.  Warfarin dose requirement in patients having severe thrombosis or thrombophilia.

Authors:  Tuukka A Helin; Lotta Joutsi-Korhonen; Heidi Asmundela; Mikko Niemi; Arto Orpana; Riitta Lassila
Journal:  Br J Clin Pharmacol       Date:  2019-06-17       Impact factor: 4.335

Review 4.  Genetic Testing in Clinical Settings.

Authors:  Nora Franceschini; Amber Frick; Jeffrey B Kopp
Journal:  Am J Kidney Dis       Date:  2018-04-11       Impact factor: 8.860

5.  Clinical Pharmacogenomics: Applications in Nephrology.

Authors:  Solomon M Adams; Karryn R Crisamore; Philip E Empey
Journal:  Clin J Am Soc Nephrol       Date:  2018-05-23       Impact factor: 8.237

Review 6.  Biomarkers of adverse drug reactions.

Authors:  Daniel F Carr; Munir Pirmohamed
Journal:  Exp Biol Med (Maywood)       Date:  2017-09-26

7.  PRECISION MEDICINE: FROM DIPLOTYPES TO DISPARITIES TOWARDS IMPROVED HEALTH AND THERAPIES.

Authors:  Dana C Crawford; Alexander A Morgan; Joshua C Denny; Bruce J Aronow; Steven E Brenner
Journal:  Pac Symp Biocomput       Date:  2018

8.  VKORC1-1639A allele influences warfarin maintenance dosage among Blacks receiving warfarin anticoagulation: a retrospective cohort study.

Authors:  Fatima Donia Mili; Tenecia Allen; Paula Weinstein Wadell; W Craig Hooper; Christine De Staercke; Christopher J Bean; Cathy Lally; Harland Austin; Nanette K Wenger
Journal:  Future Cardiol       Date:  2017-12-08

9.  Rationale, design, and preliminary results of the Quebec Warfarin Cohort Study.

Authors:  Sylvie Perreault; Payman Shahabi; Robert Côté; Stéphanie Dumas; Étienne Rouleau-Mailloux; Yassamin Feroz Zada; Sylvie Provost; Ian Mongrain; Marc Dorais; Thao Huynh; Simon Kouz; Ariel Diaz; Mark Blostein; Simon de Denus; Jacques Turgeon; Jeffrey Ginsberg; Jacques Lelorier; Lyne Lalonde; Lambert Busque; Jeannine Kassis; Mario Talajic; Jean-Claude Tardif; Marie-Pierre Dubé
Journal:  Clin Cardiol       Date:  2018-05-15       Impact factor: 2.882

10.  Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy.

Authors:  Kimberly S Collins; Victoria M Pratt; Wesley M Stansberry; Elizabeth B Medeiros; Karthik Kannegolla; Marelize Swart; Todd C Skaar; Arlene B Chapman; Brian S Decker; Ranjani N Moorthi; Michael T Eadon
Journal:  Pharmacogenet Genomics       Date:  2019-01       Impact factor: 2.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.